{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:56:51Z","timestamp":1789865811894,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.conb.2013.05.005","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T06:16:25Z","timestamp":1372227385000},"page":"692-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Pharmacotherapy for alcohol dependence: status of current treatments"],"prefix":"10.1016","volume":"23","author":[{"given":"Johan","family":"Franck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Jayaram-Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2013.05.005_bib0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"61","author":"Grant","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0010","series-title":"Global Status Report on Alcohol and Health Analysis","author":"WHO","year":"2011"},{"key":"10.1016\/j.conb.2013.05.005_bib0015","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorder","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2013.05.005_bib0020","series-title":"European Medicines Agency Recommends Approval of Medicine for Reduction of Alcohol Consumption","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.conb.2013.05.005_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/appi.ajp.2010.08101500","article-title":"Medication treatment of different types of alcoholism","volume":"167","author":"Johnson","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0030","first-page":"300","article-title":"Medications for unhealthy alcohol use","volume":"33","author":"O\u2019Malley","year":"2011","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.conb.2013.05.005_bib0035","first-page":"1335","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1600-0773.1948.tb03350.x","article-title":"The sensitizing effect of tetraethylthiuramdisulphide (antabuse) to ethylalcohol","volume":"4","author":"Hald","year":"1948","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.conb.2013.05.005_bib0045","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism: a Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.conb.2013.05.005_bib0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment for alcohol dependence","volume":"161","author":"Chick","year":"1992","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0055","series-title":"Treating Alcohol and Drug Abuse: An Evidence Based Review","year":"2003"},{"key":"10.1016\/j.conb.2013.05.005_bib0060","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","article-title":"Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment","volume":"16","author":"Krampe","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.conb.2013.05.005_bib0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050169","article-title":"Endogenous opioid system and alcohol addiction","volume":"129","author":"Hertz","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2013.05.005_bib0070","first-page":"202","article-title":"Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system","volume":"22","author":"Gianoulakis","year":"1998","journal-title":"Alcohol Health Res World"},{"key":"10.1016\/j.conb.2013.05.005_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0741-8329(95)02038-1","article-title":"Naltrexone in the treatment of alcoholism: a clinical review","volume":"13","author":"O\u2019Brien","year":"1996","journal-title":"Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0080","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0091-3057(02)00721-9","article-title":"A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited access procedure in rats","volume":"72","author":"Stromberg","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.conb.2013.05.005_bib0085","first-page":"1207","article-title":"Duration of occupancy of opiate receptors by naltrexone","volume":"29","author":"Lee","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1016\/j.conb.2013.05.005_bib0090","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(99)00147-5","article-title":"Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects","volume":"22","author":"McCaul","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2013.05.005_bib0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","author":"O\u2019Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","article-title":"Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials","volume":"36","author":"Streeton","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1360-0443.2004.00763.x","article-title":"Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review","volume":"99","author":"Bouza","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.conb.2013.05.005_bib0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145704004997","article-title":"Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials","volume":"8","author":"Srisurapanont","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Veterans affairs naltrexone cooperative study 425 group","volume":"345","author":"Krystal","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2013.05.005_bib0125","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","article-title":"A 6-month controlled naltrexone study: combined effect with cognitive behavior therapy in outpatient treatment of alcohol dependence","volume":"27","author":"Balldin","year":"2003","journal-title":"Alcohol: Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0130","first-page":"1634","article-title":"Naltrexone and cue exposure with coping and communications skills training for alcoholics: treatment process and 1-year outcomes","volume":"25","author":"Monti","year":"2001","journal-title":"Alcohol: Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0135","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2013.05.005_bib0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence","volume":"359","author":"Anton","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2013.05.005_bib0145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence: role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0155","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","article-title":"Vivitrex\u00ae, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats","volume":"28","author":"Bartus","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2013.05.005_bib0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","article-title":"Biodegradation and biocompatibility of PLA and PLGA microspheres","volume":"28","author":"Shive","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.conb.2013.05.005_bib0165","series-title":"Biodegradable Polymers as Drug Delivery Systems","first-page":"1","article-title":"Controlled release of bioactive agents from lactide\/glycolide polymers","author":"Lewis","year":"1990"},{"key":"10.1016\/j.conb.2013.05.005_bib0170","first-page":"741","article-title":"Naltrexone long acting formulation in the treatment of alcohol dependence","volume":"3","author":"Johnson","year":"2007","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.conb.2013.05.005_bib0175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","article-title":"Single and multiple dose pharmacokinetics of long-acting naltrexone","volume":"30","author":"Dunbar","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0180","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.2010.05900.x","article-title":"Intramuscular extended-release naltrexone: current evidence","volume":"1216","author":"Gastfriend","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.conb.2013.05.005_bib0185","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1530-0277.2008.00843.x","article-title":"Effect of extended release naltrexone (XR-NTX) on quality of life in alcohol dependent patients","volume":"33","author":"Pettinati","year":"2009","journal-title":"Alcohol: Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0190","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0195","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.conb.2013.05.005_bib0200","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2174\/138161210791516459","article-title":"Efficacy and tolerability of naltrexone in the management of alcohol dependence","volume":"16","author":"Garbutt","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.conb.2013.05.005_bib0205","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","article-title":"Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes","volume":"271","author":"Emmerson","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.conb.2013.05.005_bib0210","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.conb.2013.05.005_bib0215","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","article-title":"Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist","volume":"27","author":"Dixon","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00000542-198602000-00008","article-title":"Prolonged antagonism of opioid action with intravenous nalmefene in man","volume":"64","author":"Gal","year":"1986","journal-title":"Anesthesiology"},{"key":"10.1016\/j.conb.2013.05.005_bib0225","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol: Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0235","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_sbref0240","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0245","doi-asserted-by":"crossref","unstructured":"Gual A, He Y, Torup L, Brink WM, Mann K, for the ESENSE2 Study Group: A randomised, double-blind, placebo-controlled, efficacy study of nalmefene as-needed use in patients with alcohol dependence. Eur Neuropsychopharmacol, 2013, http:\/\/dx.doi.org\/10.1016\/j.euroneuro.2013.02.006.","DOI":"10.1016\/j.euroneuro.2013.02.006"},{"key":"10.1016\/j.conb.2013.05.005_bib0250","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s002130050730","article-title":"Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress","volume":"139","author":"Spanagel","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2013.05.005_bib0255","series-title":"Drugs for Relapse Prevention of Alcoholism","first-page":"73","article-title":"Acamprosate: preclinical data","author":"De Witte","year":"2005"},{"key":"10.1016\/j.conb.2013.05.005_bib0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(95)00344-K","article-title":"Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum","volume":"283","author":"Rossetti","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-4927(98)00016-X","article-title":"Central effects of acamprosate. Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats","volume":"82","author":"Dahchour","year":"1998","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-009-1515-6","article-title":"The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial","volume":"205","author":"Hammarberg","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2013.05.005_bib0275","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol dependent individuals: results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0280","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation","volume":"40","author":"Mason","year":"2006","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0285","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioural interventions for alcohol dependence\u2014the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.conb.2013.05.005_bib0290","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15288\/jsad.2008.69.878","article-title":"Do patients with alcohol dependence respond to placebo? Results from the COMBINE study","volume":"69","author":"Weiss","year":"2008","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.conb.2013.05.005_bib0295","doi-asserted-by":"crossref","first-page":"186","DOI":"10.15288\/jsad.2009.70.186","article-title":"Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study","volume":"70","author":"LoCastro","year":"2009","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.conb.2013.05.005_sbref0300","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study","author":"Mann","year":"2012","journal-title":"Addict Biol"},{"key":"10.1016\/j.conb.2013.05.005_bib0305","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.conb.2013.05.005_bib0310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10550490701756120","article-title":"Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials","volume":"17","author":"Kranzler","year":"2008","journal-title":"Am J Addict"},{"key":"10.1016\/j.conb.2013.05.005_bib0315","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.2174\/138161210791516341","article-title":"Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy","volume":"16","author":"Kiefer","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.conb.2013.05.005_bib0320","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.conb.2013.05.005_bib0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-004-1991-7","article-title":"Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients","volume":"178","author":"Verheul","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2013.05.005_bib0330","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","article-title":"Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data","volume":"36","author":"Mason","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nn1181","article-title":"Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system","volume":"7","author":"Cruz","year":"2004","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.conb.2013.05.005_bib0340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/11597320-000000000-00000","article-title":"Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence","volume":"26","author":"Muzyk","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.conb.2013.05.005_bib0345","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0350","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2013.05.005_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0360","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/JCP.0b013e31824929b2","article-title":"High-dose baclofen for treatment-resistant alcohol dependence","volume":"32","author":"Pastor","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0365","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","article-title":"Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Addolorato","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0370","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/alcalc\/agl091","article-title":"Suppression of symptoms of alcohol dependence and craving using high-dose baclofen","volume":"42","author":"Bucknam","year":"2007","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.conb.2013.05.005_bib0375","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.3748\/wjg.v16.i39.4905","article-title":"Alcoholic hepatitis: a clinician's guide to diagnosis and therapy","volume":"16","author":"Amini","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.conb.2013.05.005_bib0380","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1360-0443.2011.03752.x","article-title":"Alcohol-dependence: the current French craze for baclofen","volume":"107","author":"Rolland","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.conb.2013.05.005_bib0385","unstructured":"AFSSAPS (Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9. Utilisation hors AMM du baclof\u00e8ne dans le traitement de l\u2019alcoolo-d\u00e9pendance\u2014point d\u2019information 06\/06\/11 [Off-label use of baclofen in the treatment of alcohol-dependence. Information Point]. http:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/b88517d4324d10054712c930f22c464b.pdf."},{"key":"10.1016\/j.conb.2013.05.005_bib0390","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00023210-200519100-00005","article-title":"Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function","volume":"19","author":"Johnson","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.conb.2013.05.005_bib0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neuroscience.2005.03.045","article-title":"Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems","volume":"134","author":"Okada","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.conb.2013.05.005_bib0400","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.conb.2013.05.005_bib0405","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.conb.2013.05.005_bib0410","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","article-title":"Using topiramate or naltrexone for the treatment of alcohol-dependent patients","volume":"32","author":"Fl\u00f3rez","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0415","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4088\/JCP.08r04062gry","article-title":"Topiramate in the treatment of substance-related disorders: a critical review of the literature","volume":"71","author":"Shinn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0420","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking","volume":"104","author":"Steensland","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2013.05.005_bib0425","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.conb.2013.05.005_bib0500","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","author":"Litten","year":"2013","journal-title":"J Addict Med"},{"key":"10.1016\/j.conb.2013.05.005_bib0430","first-page":"S202","article-title":"The ethanol\u2013nAChR interaction and its relevance for modulating ethanol consumption in rodents and man","author":"S\u00f6derpalm","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0435","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00702-007-0784-7","article-title":"Stimulating and inhibitory effects of the dopamine \u201cstabilizer\u201d (\u2212)-OSU6162 on dopamine D2 receptor function in vitro","volume":"14","author":"Lahti","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.conb.2013.05.005_sbref0440","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2012.06.018","article-title":"The monoamine stabilizer (\u2212)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens","volume":"72","author":"Steensland","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0445","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1517\/13543784.2012.703179","article-title":"Pregabalin in clinical psychiatry and addiction: pros and cons","volume":"21","author":"Martinotti","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.conb.2013.05.005_bib0450","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1177\/0269881109102623","article-title":"Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial","volume":"24","author":"Martinotti","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.conb.2013.05.005_bib0455","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_bib0460","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","article-title":"Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms","volume":"29","author":"Anton","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.conb.2013.05.005_sbref0465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.conb.2013.05.005_sbref0470","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/978-3-642-28720-6_150","article-title":"Modeling relapse situations in the human laboratory","volume":"13","author":"Sinha","year":"2013","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.conb.2013.05.005_bib0475","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2012.12.017","article-title":"Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism","volume":"128","author":"Zorrilla","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.conb.2013.05.005_bib0480","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1126\/science.1153813","article-title":"Neurokinin 1 receptor antagonism as a possible therapy for alcoholism","volume":"319","author":"George","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.conb.2013.05.005_bib0485","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1530-0277.2008.00829.x","article-title":"The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats","volume":"33","author":"Rasmussen","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0490","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.conb.2013.05.005_bib0495","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438813001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438813001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:37:49Z","timestamp":1760704669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438813001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0959438813001190"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2013.05.005","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for alcohol dependence: status of current treatments","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2013.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}